Petr Novák

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · The Lancet Neurology · 2016 · 302 citations

Medicine, Immunology, Neurology +12

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Eva Kontseková, Norbert Žilka, Branislav Kováčech et al. · Alzheimer s Research & Therapy · 2014 · 244 citations · Full text

Life Sciences, Immunology, Immunization +16

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Petr Novák, Branislav Kováčech, Stanislav Katina et al. · Nature Aging · 2021 · 172 citations · Full text

Life Sciences, Neurology, Neuroscience +15

A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.

Kathleen K. Brown, Brad R. Henke, Steven G. Blanchard et al. · Diabetes · 1999 · 168 citations

Medicine, Endocrinology, Pharmacology +17

Assessment of severity and progression of canine cognitive dysfunction syndrome using the CAnine DEmentia Scale (CADES)

Aladár Maďari, Jana Farbáková, Stanislav Katina et al. · Applied Animal Behaviour Science · 2015 · 151 citations

Medicine, Neurology, Neuroscience +14